Global Leukapheresis Market Size study & Forecast, by Product Type (Leukapheresis Devices, Leukapheresis Disposables), by Application (Research Applications, Therapeutic Applications), by End-User (Hospitals & Transfusion Centers, Component Providers & Bl

Global Leukapheresis Market Size study & Forecast, by Product Type (Leukapheresis Devices, Leukapheresis Disposables), by Application (Research Applications, Therapeutic Applications), by End-User (Hospitals & Transfusion Centers, Component Providers & Blood Centers, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies) and Regional Analysis, 2022-2029

Global Leukapheresis Market is valued at approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XXX% over the forecast period 2022-2029. Leukapheresis is used in the treatment of leukaemia or patients with high white blood cells. White blood cell levels in hematopoietic cells, such as persistent leukaemias, may be high enough to result in leukostasis. Changes in eyesight, shortness of breath due to less effective oxygen exchange, and other organ systems may be affected by this. Leukapheresis can therefore be carried out to collect the patient's blood cells for a subsequent transplant. Rarely is leukapheresis—which is typically for granulocytes—performed during the blood donation process. The key factors driving the market growth are the rising number of blood donations and increasing demand for leukopaks in clinical research that is anticipated to create a lucrative demand for the market during forecast period.

Also, the growing incidence of leukemia is propelling the lucrative demand for the market. The International Agency for Research on Cancer (IARC) estimates that there were around 437,033 new cases of leukaemia worldwide in 2018 and that there were 309,006 leukemia-related deaths. Additionally, the rising number of blood donations is anticipated to drive market growth. The demand for blood and blood products is growing every year in many regions - particularly low- and middle-income countries. Blood and blood products assist intricate medical and surgical procedures, extend the lives of patients with life-threatening diseases, and improve their quality of life. The American National Red Cross 2020 estimates that around 21 million blood components are transplanted annually in the U.S. However, leukapheresis for pediatric patients creates a lucrative opportunity for the market. Also, the high cost of Therapeutic Leukapheresis stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Leukapheresis Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key players, rising prevalence of leukemia, and well-developed healthcare infrastructure. Whereas, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period, owing to factors such as rise in prevalence of leukemia in this region, technological advancements, and rise in government initiatives to promote healthy lifestyles which would create lucrative growth prospects for the Leukapheresis market across Asia Pacific region.

Major market players included in this report are:
Asahi Kasei Corporation (Japan)
Fresenius SE & Co. KGaA (Germany)
Haemonetics Corporation (US)
Terumo BCT (US)
Macopharma SA (France)
Miltenyi Biotec (Germany)
Guangzhou Daji Medical Science and Technology Co. Ltd. (China)
MEDICA S.p.A (Italy)
PuriBlood Medical Co. Ltd. (Taiwan)
Beijing ZKSK Technology Co. Ltd. (China)
Recent Developments in the Market:
In February 2022, Cryoport Inc. joined a partnership agreement with Cell Matters SA to deliver edge cryopreservation solutions for leukapheresis-derived therapies enabling both autologous and allogeneic cell treatments to the life sciences industry.

Global Leukapheresis Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product Type, Application, End-User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product Type
Leukapheresis Devices
Leukapheresis Disposables

By Application:
Research Applications
Therapeutic Applications

By End-User:
Hospitals & Transfusion Centers
Component Providers & Blood Centers
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned
Asahi Kasei Corporation (Japan)
Fresenius SE & Co. KGaA (Germany)
Haemonetics Corporation (US)
Terumo BCT (US)
Macopharma SA (France)
Miltenyi Biotec (Germany)
Guangzhou Daji Medical Science and Technology Co. Ltd. (China)
MEDICA S.p.A (Italy)
PuriBlood Medical Co. Ltd. (Taiwan)
Beijing ZKSK Technology Co. Ltd. (China)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.